BOULDER, Colo.– Integrated DNA Technologies (IDT), a global leader in genomics, announced a strategic partnership with Hamilton (Hamilton Company and Hamilton Bonaduz AG), a worldwide leader in precision laboratory automation, to deliver complete automation-ready solutions for next generation sequencing (NGS).
Under the agreement, the companies will develop automation scripts for IDT’s xGen™ and Archer™ NGS products to be used on Hamilton’s Microlab® STAR™ and NIMBUS® liquid handling platforms. This integration is designed to give laboratories worldwide customizable, automation-friendly NGS workflows for solid tumor, heme, and other comprehensive genomic profiling applications.
“At IDT, we believe that innovation happens when scientists have the freedom to design workflows that fit their research needs,” said Ajay Gannerkote, President of IDT. “By pairing IDT’s flexible NGS solutions with Hamilton’s automation expertise, we’re removing constraints that may arise from one-size-fits-all approaches so labs can consistently and reliably accelerate their discoveries with confidence, precision and speed, at whatever scale their work demands.”
Michael Mouradian, Vice President of Scientific Strategy and Market Development at Hamilton, added: “Hamilton is proud to partner with IDT to bring flexible, automation-ready NGS workflows to the global research community. By combining Hamilton’s precision engineering and trusted liquid handling platforms with IDT’s innovative assay solutions, we are enabling laboratories to achieve greater scalability, consistency, and efficiency in their genomic discoveries. The partnership reflects Hamilton’s commitment to empowering scientists with solutions that accelerate breakthroughs in research and beyond.”
The collaboration underscores IDT’s mission to provide modular, scalable solutions that adapt to evolving research demands. For researchers, the partnership is expected to reduce time spent on manual processes and increase the efficiency of data generation, ultimately driving faster progress in cancer and other genomic research.
